What Happened?
South San Francisco, CA-based Cortexyme Appointed Casey Lynch as Chief Executive Officer
About the Company
Cortexyme is developing therapeutics based on data supporting a new theory of the cause of Alzheimer`s and other neurodegenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently testing several potential lead therapeutics in preclinical studies.
About the Person
Casey Lynch is CEO at Cortexyme.
Info Source
Press Release
Short Profile